Shinpoong Pharmaceutical Co. Ltd., based in South Korea, is a high-risk company in the pharmaceutical industry with a risk rating score of 35.4. Specializing in manufacturing remedy drugs and active pharmaceutical ingredients, Shinpoong Pharmaceutical offers a variety of products including Newsicam, Caravenal, Roxagen, Clamoxin duo, Ceroxim, and Clocin. With production facilities located in Gyeonggi-do and Cheongwon-gun, Shinpoong Pharmaceutical prioritizes ESG factors in its operations.